In Situ Hybridization Market Report 2025

The in situ hybridization market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to early adoption in research, evolution of molecular biology tools, diagnostic applications development, shift in biomedical research focus, increasing investment in biotechnology.

The in situ hybridization market size is expected to see rapid growth in the next few years. It will grow to $2.79 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to increasing adoption in clinical diagnostics, growth in research and development funding, automation and high-throughput solutions, expanded applications in neuroscience and pathology. Major trends in the forecast period include advancements in molecular biology, rising demand in research applications, diagnostic applications expansion, demand for personalized medicine, increased funding in biomedical research.

The rise in infectious diseases is projected to drive the growth of the in-situ hybridization market in the coming years. Infectious diseases are conditions that can be transmitted from one person to another through contaminated food and beverages, as well as through pathogens such as viruses, bacteria, fungi, and parasites. In situ hybridization (ISH) aims to detect complementary nucleic acid sequences in tissue samples by using labeled nucleic acid sequences (probes) that are specific to the infectious organism. Thus, a rise in infectious diseases contributes to the expansion of the in-situ hybridization market. For example, in March 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Therefore, the growing prevalence of infectious diseases is fueling the growth of the in-situ hybridization market.

The upsurge in cancer cases is anticipated to fuel the growth of the in-situ hybridization market. In-situ hybridization is employed to identify specific genetic alterations in cancer cells, including gene amplifications, deletions, translocations, and rearrangements. According to the American Cancer Society (ACS), it is projected that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. Hence, the increasing incidence of cancer is a significant factor contributing to the growth of the in-situ hybridization market.

Key players in the in situ hybridization market are concentrating on creating innovative solutions, such as RNA detection assays, to enhance the development of gene therapies. An RNA detection assay is a molecular technique designed to identify and quantify specific RNA molecules within a sample, allowing for the examination of gene expression, viral infections, and various RNA-related biological processes. For example, in January 2023, Bio-Techne Corporation, a life sciences company based in the U.S., introduced the RNAscope Plus smRNA-RNA detection assay. This advanced in situ hybridization tool enables the simultaneous fluorescent detection of small regulatory RNAs, including microRNAs (miRNAs), alongside three target RNAs or RNA biomarkers within the same tissue section. The assay offers single-cell and subcellular resolution, allowing researchers to evaluate the biodistribution and functionality of novel gene therapies and endogenous regulatory RNAs effectively. It is designed for scalability to support large-scale studies and can be used on the Leica Bond Rx platform or as a manual assay. By combining proprietary RNAscope and miRNAscope technologies, this assay significantly enhances the understanding of gene expression and cellular responses, providing essential insights for the development of personalized gene therapies for both inherited and acquired diseases.

Major companies operating in the in-situ hybridization market are driving profitability through innovative product solutions, such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). HCR RNA-CISH is a technique that facilitates the visualization of RNA molecules in cells and tissues with high resolution and sensitivity. In February 2023, Molecular Instruments (MI) launched HCR RNA-CISH to enhance automated chromogenic in-situ hybridization workflows, providing better performance than existing approaches with reduced turnaround time and cost. It also features native support for Immunohistochemistry (IHC) codetection and full compatibility with major automation platforms.

In January 2023, Agilent Technologies Inc., a life sciences company based in the U.S., acquired Avida Biomed Inc. for an undisclosed sum. This acquisition is intended to bolster Agilent's capabilities in genomics and broaden its range of innovative tools for researchers, especially in next-generation sequencing and biomolecular analysis. Avida Biomed Inc. is a U.S.-based biotechnology firm that focuses on creating cutting-edge diagnostic solutions and assays for a variety of medical applications.

Major companies operating in the in situ hybridization market include Thermo Fisher Scientific Inc., Bio SB Inc., BioGenex Laboratories, Advanced Cell Diagnostics Inc., Exiqon A/S, Agilent Technologies Inc., F. Hoffmann-La Roche AG, Abbott Laboratories Inc., Merck KGaA, PerkinElmer Inc., Biocare Medical LLC, Genemed Biotechnologies, Danaher Corporation, Leica Biosystems Nussloch GmbH, Bio-Rad Laboratories Inc., Oxford Gene Technology, Abnova Corporation, Qiagen, Bio-Techne Corporation, Biochain Institute Inc., Cytocell Ltd., Enzo Life Sciences Inc., Eurofins Scientific SE, FISH Technologies Sdn Bhd, Genetix Biotech Asia Pvt. Ltd., Zytomed System GmbH, Akoya Biosciences Inc., Becton Dickinson and Company (BD), DAKO Systemtechnik und Service GmbH & Co, Molecular Devices LLC., NanoString Technologies Inc., Visiopharm A/S.

North America was the largest region in the in situ hybridization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global in situ hybridization market duirng the forecast period. The regions covered in the in situ hybridization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in situ hybridization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

In-situ hybridization is a method that facilitates the precise localization of a specific nucleic acid segment within a histologic slice. This technique is employed for identifying sequences of nucleotides in tissues, encompassing complete tissues, portions of tissues, and individual cells.

The primary types of in-situ hybridization products include analytical instruments, kits and reagents, software and services, among others. Analytical instruments are designed to assist researchers in detecting and visualizing specific nucleic acid sequences within cells or tissues. Various techniques involved in this process include fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH), which utilize different types of probes such as DNA and RNA. These techniques find applications in diverse areas, including cancer research, cytogenetics, developmental biology, infectious diseases, and more. The end users of these products include research and diagnostic laboratories, contract research organizations (CROs), academic institutes, and others.

The in situ hybridization market research report is one of a series of new reports that provides in situ hybridization market statistics, including in situ hybridization industry global market size, regional shares, competitors with an in situ hybridization market share, detailed in situ hybridization market segments, market trends and opportunities, and any further data you may need to thrive in the in situ hybridization industry. This in situ hybridization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The In-situ hybridization market includes revenues earned by entities by providing in-situ hybridization with synthetic oligonucleotides probes, double-stranded DNA (dsDNA) probes, and single-stranded DNA (dsDNA) probes. The market value includes the value of related goods sold by the service provider or included within the service offering. The In-situ hybridization market also includes sales of linear hybridization chain reaction techniques and non-linear hybridization chain reaction techniques. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.